OVID · Ovid Therapeutics Inc.
$2.33
-0.01 (-0.43%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$468.71M
Shares
195.30M
Volume · Oct 6
160.63K
Avg daily vol (3M)
1.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.34
Open$2.38
Day$2.29–2.47
52W close$1.20–2.96
Avg vol 30d1.6M
Short int21.2M · 10.8% float · 17.3d
Short vol59%
Last earningsMar 18, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.58M
Trailing 12 months
Net income (TTM)
−$34.49M
Trailing 12 months
Revenue growth YoY
-88.3%
Year over year
Operating margin
-3,686.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$11.33M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.5%
Year over year · more shares
Price change (1Y)
+27.2%
Trailing year
Short interest
10.8%
Latest settlement · 17.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−11%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
65%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−21%
trailing
YTD return
+44%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.83% of float · ▲ +2.3% MoM · 17.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
131 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
+1181%
Y/Y
EPS growth
+4%
Y/Y
Free cash flow
$-38.3M
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−11%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
65%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +46 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.83% of float · ▲ +2.3% MoM · 17.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
131 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 65%
Range high $3
vs 200-day avg +2%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OVID
this stock
Ovid Therapeutics Inc.
|
$468.71M | +43.6% | +1181.3% | — | 10.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OVID | -4.9% | -16.4% | -21.0% | -6.0% | +43.6% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -6.1% | -17.0% | -32.5% | -7.6% | +29.9% |